Arrhythmia Research Technology (HRT) Reports Q2 EPS of $0.02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- US stock futures muted as oil holds near April highs ahead of Fed decision
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Arrhythmia Research Technology, Inc. Reports 2016 Second Quarter Results
August 11, 2016 4:15 PM EDTFITCHBURG, MA -- (Marketwired) -- 08/11/16 -- Arrhythmia Research Technology, Inc. (NYSE MKT: HRT) (the "Company"), through its wholly-owned subsidiary, Micron Products, Inc., a diversified contract manufacturing organization that produces highly-engineered, innovative medical device components requiring precision machining and injection molding, announced results for its second quarter ended June 30, 2016.
"I am pleased with the Company's return to profitability and our continued improvement in operating performance in the second quarter of 2016. When compared to the first quarter of 2016, net sales increased $146 thousand, gross margin increased 4.7 points and we posted a profit by improving our bottom... More



